Spruce Street Capital LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 13, 2026. SEC CIK 2050194.
- Reported value$509.7m
- Positions30
Holdings: 30 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International | ORD SHS CL A | G52694109 | 58.7 | 11.5% | 918,070 | Added+157,007 | |
| Relay Therapeutics IncRLAY | COM | 75943R102 | 55.8 | 11.0% | 2,984,125 | Unchanged | |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 44.7 | 8.8% | 1,376,159 | Unchanged | |
| Relmada Therapeutics IncRLMD | COM | 75955J402 | 44.2 | 8.7% | 6,391,328 | Added+129,214 | |
| Alto Neuroscience IncANRO | COM SHS | 02157Q109 | 35.7 | 7.0% | 1,353,047 | Added+27,837 | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 34.6 | 6.8% | 354,816 | Reduced−18,458 | |
| Alkermes plc | SHS | G01767105 | 28.5 | 5.6% | 543,876 | Added+225,884 | |
| Savara IncSVRA | COM | 805111101 | 21.3 | 4.2% | 3,452,576 | Added+69,401 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 17.8 | 3.5% | 306,047 | Added+60,338 | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 16.7 | 3.3% | 329,006 | Unchanged | |
| Enanta Pharmaceuticals IncENTA | COM | 29251M106 | 15.9 | 3.1% | 1,088,731 | Added+156,133 | |
| Perspective Therapeutics IncCATX | COM NEW | 46489V302 | 12.6 | 2.5% | 3,693,931 | Added+1,066,824 | |
| Inflarx NV | COM | N44821101 | 12.0 | 2.4% | 5,352,198 | New+5,352,198 | |
| Surrozen IncSRZN | COM NEW | 86889P208 | 11.2 | 2.2% | 432,040 | Unchanged | |
| Alumis IncALMS | COM | 022307102 | 11.0 | 2.2% | 392,574 | Unchanged | |
| Century Therapeutics IncIPSC | COM | 15673T100 | 9.9 | 2.0% | 4,059,054 | Unchanged | |
| Minerva Neurosciences IncNERV | COM NEW | 603380205 | 9.2 | 1.8% | 1,655,500 | Unchanged | |
| SAB Biotherapeutics IncSABS | COM NEW | 78397T202 | 8.6 | 1.7% | 2,198,502 | Unchanged | |
| AN2 Therapeutics IncANTX | COM | 037326105 | 8.0 | 1.6% | 1,661,073 | Unchanged | |
| Erasca IncERAS | COM | 29479A108 | 7.7 | 1.5% | 422,543 | Unchanged | |
| Inhibikase Therapeutics IncIKT | COM NEW | 45719W205 | 7.3 | 1.4% | 3,581,603 | Unchanged | |
| Research Alliance Corp III | ORD SHS CL A | G75226103 | 5.4 | 1.0% | 500,000 | New+500,000 | |
| Helix Acquisition Corp III | USD CL A ORD SHS | G4444S107 | 5.3 | 1.0% | 500,000 | Unchanged | |
| ZAI Lab LtdZLAB | ADR | 98887Q104 | 5.3 | 1.0% | 279,110 | New+279,110 | |
| Achieve Life Science IncACHV | COM | 004468500 | 4.8 | 0.9% | 736,637 | New+736,637 | |
| Lexeo Therapeutics IncLXEO | COM | 52886X107 | 4.3 | 0.8% | 928,593 | Unchanged | |
| Alector IncALEC | COM | 014442107 | 4.2 | 0.8% | 2,101,068 | Unchanged | |
| Leonabio IncLONA | COM | 04746L203 | 3.6 | 0.7% | 393,701 | Unchanged | |
| Corvus Pharmaceuticals IncCRVS | COM | 221015100 | 3.5 | 0.7% | 231,585 | Unchanged | |
| Jatt II Acquisition Corp | ORD SHS | G50765109 | 1.8 | 0.4% | 160,000 | New+160,000 |
Sold out: 3 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−489,849 | |
| Kalvista Pharmaceuticals | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−897,681 | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 0.0 | 0.0% | 0 | Sold out−200,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0002050194-26-000005 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.